Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Share-based Compensation (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Share-based Compensation for 6 consecutive years, with $314000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 54.76% to $314000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $671000.0, a 91.15% decrease, with the full-year FY2024 number at $762000.0, up 775.86% from a year prior.
  • Share-based Compensation was $314000.0 for Q3 2025 at Vivos Therapeutics, up from $300000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.5 million in Q2 2024 to a low of -$913000.0 in Q4 2023.
  • A 5-year average of $890437.5 and a median of $332000.0 in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 2945.0% in 2022, then tumbled 217.81% in 2023.
  • Vivos Therapeutics' Share-based Compensation stood at $2.6 million in 2021, then crashed by 70.62% to $775000.0 in 2022, then crashed by 217.81% to -$913000.0 in 2023, then soared by 106.24% to $57000.0 in 2024, then soared by 450.88% to $314000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Share-based Compensation are $314000.0 (Q3 2025), $300000.0 (Q1 2025), and $57000.0 (Q4 2024).